CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

DELFI identifies circulating fragments of DNA (cfDNA) and plasma biomarkers to detect cancer. Participants will be enrolled into the DELFI-L201 study after informed consent and eligibility is confirmed. The study purpose is to validate the performance of the DELFI-based test for the detection of lung cancer among individuals eligible for routine lung cancer screening. Participants will have blood collected and medical record review at baseline and will have medical record reviews at additional timepoints.

Inclusion criteria

• All subjects

• Ability to understand and provide written informed consent
• Age ≥ 50 years
• Current or former smoker
• ≥ 20 pack-years (pack years = number of packs per day × number of years smoked)
• An initial or annual follow-up lung cancer screening chest CT planned/scheduled within 30 days after enrollment (i.e., enrollment chest CT scan)

Exclusion criteria

• All subjects

• Evidence of any diagnosed cancer (including prior lung cancer) other than non-melanoma skin cancer or carcinoma in situ within 2 years prior to enrollment
• Prior systemic therapy, definitive therapy, radiation, or surgical resection for any cancer diagnosis within 2 years prior to enrollment (with the exception of surgery for nonmelanoma skin cancer and biopsies)
• Any history of hematologic malignancy or myelodysplasia within 2 years prior to enrollment
• Any history of organ tissue transplantation
• Any history of blood product transfusion within 120 days prior to enrollment
• Current pregnancy
• Any condition that in the opinion of the Investigator should preclude the participant's participation in the study
• Past or current participation in any clinical study sponsored by DELFI Diagnostics or any history of a LDT (Laboratory Developed Test) for early detection of lung cancer by DELFI Diagnostics